News & Updates

Uromodulin, as a protein and genetic biomarker, is not a reliable predictor of hypertension or hypertension-related outcomes, reveals a study. However, it may have potential use in the prediction of other cardiovascular outcomes.

In the phase IV VICTORION-Challenge trial, inclisiran outperforms bempedoic acid (BPA) for lowering LDL-C in individuals with high and very high cardiovascular (CV) risk.

In the SHASTA-3 and SHASTA-4 trials, quarterly administration of plozasiran reduced triglyceride (TG) levels and acute pancreatitis (AP) events in individuals with severe hypertriglyceridaemia (sHTG; TG ≥500 mg/dL).